AstraZeneca Fails to Prove the Drug Selumetinib for Thyroid cancer

 AstraZeneca Fails to Prove the Drug Selumetinib for Thyroid cancer

AstraZeneca Fails to Prove the Drug Selumetinib for Thyroid cancer

Shots:
  • The drug failed to meet the primary endpoint of thyroid cancer lead to its failure as well as removal from phase 3, double blind involved in high risk DTC
  • The licensor AstraZeneca refused to pay royalties to the license Array pharma for the drug
  • AstraZeneca to pay $192million according to licensing deal to Array Pharma
Click here to read full press release/ article | Ref: Array Biopharma | Image:Bloomberg

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post